Anne Maitland, MD, discusses mast cell activation in health. Dr Maitland also reviews mast cell activation disease, including mast cell activation syndrome, and primary immunodeficiency as a form of secondary mast cell activation disease.
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
